推荐产品
产品线
BioReagent
质量水平
方案
≥98%
表单
powder
分子量
Mw 123.11 g/mol
技术
cell culture | insect: suitable
cell culture | mammalian: suitable
cell culture | plant: suitable
颜色
white to off-white
pH值（酸碱度）
3.4 (20 °C, 10 g/L)
mp
236-239 °C (lit.)
溶解性
1 M NaOH: soluble 50 mg/mL, clear, colorless to very faintly yellow
密度
1.473 g/cm3 at 25 °C
应用
agriculture
SMILES字符串
OC(=O)c1cccnc1
InChI
1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)
InChI key
PVNIIMVLHYAWGP-UHFFFAOYSA-N
基因信息
human ... CYP1A2(1544)
rat ... Chrnb2(54239)
正在寻找类似产品? 访问 产品对比指南
警示用语：
Warning
危险声明
危险分类
Eye Irrit. 2
储存分类代码
11 - Combustible Solids
WGK
WGK 1
闪点(°F)
379.4 °F - closed cup
闪点(°C)
193 °C - closed cup
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
从最新的版本中选择一种：
分析证书(COA)
Lot/Batch Number
Koon K Teo et al.
Stroke, 44(10), 2688-2693 (2013-07-25)
In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental
John R Guyton et al.
Journal of the American College of Cardiology, 62(17), 1580-1584 (2013-08-07)
This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial. During a
Beat Müller et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 20(2), 181-195 (2003-10-11)
A novel methodology for establishing a pharmacological dose-effect relationship of methyl nicotinate, hexyl nicotinate and nicotinic acid acting as peripheral vasodilators in the skin following topical application is investigated. This methodology involves the estimation of the unbound drug concentration in
Paul M Lavigne et al.
Journal of the American College of Cardiology, 61(4), 440-446 (2012-12-26)
This study sought to assess the efficacy of niacin for reducing cardiovascular disease (CVD) events, as indicated by the aggregate body of clinical trial evidence including data from the recently published AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High
Martina Lukasova et al.
Trends in pharmacological sciences, 32(12), 700-707 (2011-09-29)
Nicotinic acid (niacin) has been used for decades to prevent and treat atherosclerosis. The well-documented antiatherogenic activity is believed to result from its antidyslipidemic effects, which are accompanied by unwanted effects, especially a flush. There has been renewed interest in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门